Long-term trial supports CD19-targeted CAR T cells for relapsed/refractory CLL
0 Views
administrator
07/14/23
In this episode, Mark Geyer and colleagues demonstrate that second-generation CD19-targeted CAR T cell therapy following conditioning chemotherapy is tolerated in patients with relapsed/refractory CLL and can result in complete remission in a subset of patientsโฆ
Show more
Facebook Comments
No comments found